Sudeep Pharma Share Price, IPO GMP, Results, Returns and Should You Buy

Last updated: 31, October 2026

The Sudeep Pharma share price today is around ₹1,103 on the NSE, up roughly 8% on the day from a previous close of ₹1,022. The Vadodara-based pharmaceutical excipients and specialty chemicals maker listed on 28 November 2025 after a ₹895 crore IPO that was subscribed about 94 times, opening at a 23% premium. The stock has since moved between a 52-week low of ₹524 and a high of ₹1,378, and recent sessions have been volatile. This guide covers the latest NSE snapshot, recent sessions, the IPO and its GMP trend, business overview, financial highlights, valuation, technical levels, shareholding and a balanced answer to the question most readers ask: should you buy Sudeep Pharma now?

Sudeep Pharma Share Price Today: Live Snapshot

Sudeep Pharma Last Trading Sessions

The stock traded above ₹1,100 in early October, slid to the ₹950–1,000 zone in the third week, and has now bounced sharply back above ₹1,100 in a single session. Daily moves of 3–8% are common, so short-term swings can be large.

Sudeep Pharma IPO: Subscription, GMP and Listing Recap

The IPO is closed, so the grey market premium (GMP) no longer matters for new investors. Here is how it played out.

The GMP peaked near ₹130 in the middle of the issue, eased to around ₹85 by the close, and recovered to about ₹120 before listing. The actual listing of ₹730 was close to the grey market’s estimate, which had pointed to roughly ₹714–715.

Sudeep Pharma Business Overview

Sudeep Pharma operates three manufacturing facilities in Vadodara, Gujarat, with total capacity of around 65,579 metric tons. It holds USFDA, WHO-GMP and ISO approvals and serves more than 1,100 customers across roughly 100 countries, including large multinational names in pharma and food. The company also plans a wholly owned subsidiary, SAMPL, to pursue advanced materials based on its mineral chemistry expertise.

Pharma excipients are the inactive ingredients used to make tablets and capsules. They are a steady, quality-driven business: once a manufacturer is approved for a product, customers tend to stay for years, but they also demand strict compliance, so regulatory issues can be costly.

Sudeep Pharma Financial Highlights

Full audited financial statements for the latest year were not available for this article, so the figures below are the ones we could confirm.

EBITDA more than doubled in two years, but growth slowed sharply in FY25. Investors should check the latest quarterly results, because recent periods have shown uneven performance in revenue and profit.

Sudeep Pharma Valuation and Key Ratios

At around 60 to 70 times trailing earnings, Sudeep Pharma is priced well above typical pharma and specialty chemical peers. The market is clearly paying for expected growth, quality of the product portfolio and the strength of its regulatory approvals. Such a valuation leaves little room for disappointment.

Sudeep Pharma Shareholding

The shareholding breakdown was not confirmed for this article, so check the latest quarterly shareholding filing on the exchange website for the promoter, FII, DII and public split.

Sudeep Pharma Returns and 52-Week Range

Sudeep Pharma Technicals: Key Price Levels

The levels below come from recent price action and the latest moving averages available. They are reference points, not forecasts.

Today’s move took the stock back above its 50-day average, which is an encouraging sign for short-term traders. The 200-day average sits well below the current price, so the stock remains in a long-term uptrend, though it has been correcting from its October high.

What to Watch Next

• Quarterly results: revenue and profit growth after the slowdown seen in FY25.
• Margin trend: whether EBITDA margins hold as input costs and pricing change.
• Export and regulatory updates: new product approvals and any inspection outcomes at Vadodara plants, since these directly affect customer demand.
• Capacity utilisation: how fast the existing 65,000-plus metric tons of capacity is being filled.
• SAMPL subsidiary: progress on the advanced materials venture, which could open a new revenue line.
• Mutual fund and institutional interest: changes in fund holdings, which can signal confidence or drive short-term swings.

Should You Buy Sudeep Pharma Share Now?

No article can tell you what is right for your portfolio, so here is the evidence on both sides. This is not investment advice.

How different investors may look at it:

The honest summary: Sudeep Pharma is a well-regulated, well-capitalised specialty manufacturer that has rewarded IPO investors so far. But the valuation is demanding, earnings growth has cooled in the latest year, and the stock moves sharply on short-term news. Anyone considering it should decide their time horizon, position size and risk limit first, and speak to a SEBI-registered advisor.

Sudeep Pharma Stock Summary: Where It Stands Today

The stock is near ₹1,103, about 20% below its 52-week high of ₹1,378 and more than twice its 52-week low of ₹524. It has bounced back above its 50-day average after a choppy October, supported by strong regulatory credentials and a large plant base, but its valuation remains high relative to recent earnings growth. Bookmark this page for the latest price and results data.

Check Also: infosys share price | pranav constructions ipo gmp | sbi funds management ipo gmp | icici prudential amc ipo gmp | augmont enterprises ipo gmp

FAQs on Sudeep Pharma

Disclaimer: This article is for information only and is not investment advice. Stock prices are volatile and past performance does not guarantee future returns. Please consult a SEBI-registered advisor before investing.